---
title: GHB
description: 
published: true
date: 2026-01-29T16:29:26.536Z
tags: 
editor: markdown
dateCreated: 2026-01-27T07:15:16.934Z
---

[â—€è¿”å›](./home.md)

# GHB

<mark> ä¸é”™ï¼Œä½†æ˜¯ä»éœ€äººå·¥æ ¸å¯¹<mark>

**å½“[GABAèƒ½ç‰©è´¨](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md#GABA_receptors)ï¼ˆå¦‚GHBï¼‰ä¸[é˜¿ç‰‡ç±»è¯ç‰©](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/é˜¿ç‰‡ç±»è¯ç‰©.md)ã€[è‹¯äºŒæ°®å“ç±»ç‰©è´¨](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‹¯äºŒæ°®å“ç±»ç‰©è´¨.md)ã€[å·´æ¯”å¦¥ç±»ç‰©è´¨](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å·´æ¯”å¦¥ç±»ç‰©è´¨.md)ã€[åŠ å·´å–·ä¸ç±»ç‰©è´¨](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/åŠ å·´å–·ä¸ç±»ç‰©è´¨.md)ã€[å™»å©äºŒæ°®å“ç±»ç‰©è´¨](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å™»å©äºŒæ°®å“ç±»ç‰©è´¨.md)æˆ–[é…’ç²¾](./é…’ç²¾.md)ç­‰å…¶ä»–[æŠ‘åˆ¶å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md)è”ç”¨æ—¶ï¼Œå¯èƒ½ä¼šå‘ç”Ÿè‡´å‘½çš„[è¯ç‰©è¿‡é‡](../æ–‡æ¡£/è¯ç‰©è¿‡é‡.md)ã€‚[\[1\]](#cite_note-tripsit-1)**

å¼ºçƒˆä¸å»ºè®®è”ç”¨è¿™äº›ç‰©è´¨ï¼Œç‰¹åˆ«æ˜¯åœ¨[ä¸­ç­‰](../æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md#ä¸­ç­‰)åˆ°[ä¸¥é‡](../æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md#ä¸¥é‡)å‰‚é‡ä¸‹ã€‚

| GHB | |
| --- | --- |
| [![GHB.svg](../æ–‡ä»¶/GHB.svg)](../æ–‡ä»¶/GHB.svg) | |
| **åŒ–å­¦å‘½å** | |
| å¸¸è§åç§° | *GHB, G, Xyrem, Sodium oxybate* |
| å–ä»£åç§° | *gamma-Hydroxybutyric acid* |
| ç³»ç»Ÿå‘½å | *4-Hydroxybutanoic acid* |
| **åˆ†ç±»å½’å±** | |
| ç²¾ç¥è¯æ•ˆåˆ†ç±» | *[æŠ‘åˆ¶å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md)* |
| åŒ–å­¦åˆ†ç±» | *[Î³-ç¾ŸåŸºé…¸](https://en.wikipedia.org/wiki/Gamma-Hydroxy_acid)* |
| **[ç»™è¯é€”å¾„](../æ–‡æ¡£/ç»™è¯é€”å¾„.md)** | |
| - **è­¦å‘Š:** ç”±äºä¸ªä½“ä½“é‡ã€è€å—æ€§ã€ä»£è°¢å’Œä¸ªäººæ•æ„Ÿåº¦çš„å·®å¼‚ï¼Œè¯·åŠ¡å¿…ä»è¾ƒä½å‰‚é‡å¼€å§‹ã€‚[å¦è§è´Ÿè´£ä»»çš„ç”¨è¯ç« èŠ‚](../æ–‡æ¡£/è´Ÿè´£ä»»çš„ç”¨è¯ç´¢å¼•é¡µ.md)ã€‚ <br>   <br>    | â‡£ [å£æœ](../æ–‡æ¡£/ç»™è¯é€”å¾„.md#Oral) |
| [å‰‚é‡](../æ–‡æ¡£/ç»™è¯å‰‚é‡.md) | |
| [é˜ˆå€¼](../æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md#é˜ˆå€¼) | 0.5 g |
| [è½»å¾®](../æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md#è½»å¾®) | 0.5 - 1 g |
| [ä¸­ç­‰](../æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md#ä¸­ç­‰) | 1 - 2.5 g |
| [å¼ºçƒˆ](../æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md#å¼ºçƒˆ) | 2.5 - 4 g |
| [ä¸¥é‡](../æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md#ä¸¥é‡) | 4 g + **è­¦å‘Šï¼šè¶…è¿‡ 10 g æœ‰æ­»äº¡é£é™©[\[2\]](#cite_note-ErowidGHBVault-2)** |
| [è¯æ•ˆæ—¶é•¿](../æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md) | |
| [æ€»æ—¶é•¿](../æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md#Total) | 1.5 - 2.5 å°æ—¶ |
| [è¯æ•ˆå‘ä½œ](../æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md#Onset) | 5 - 30 åˆ†é’Ÿ |
| [è¯æ•ˆä¸Šå‡](../æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md#Come_up) | 10 - 20 åˆ†é’Ÿ |
| [è¯æ•ˆè¾¾å³°](../æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md#Peak) | 45 - 90 åˆ†é’Ÿ |
| [è¯æ•ˆè¤ªå»](../æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md#Offset) | 15 - 30 åˆ†é’Ÿ |
| [è¯æ•ˆæ®‹ä½™](../æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md#After_effects) | 2 - 4 å°æ—¶ |
| <br>   <br>   <br>   <br>   <br>   <br>   <br>   <br>    - **[å…è´£å£°æ˜](../å…³äºæœ¬ç«™/è§‚å‰æé†’.md)ï¼š** æœ¬ç«™çš„[å‰‚é‡](../æ–‡æ¡£/ç»™è¯å‰‚é‡.md)ä¿¡æ¯æ”¶é›†è‡ªç”¨æˆ·å’Œ[ç½‘ç»œ](../æ–‡æ¡£/ç§‘å­¦ä¿¡æ¯ç´¢å¼•é¡µ.md)ï¼Œä»…ç”¨äºæ•™è‚²ç›®çš„ã€‚å®ƒä¸æ˜¯æ¨èï¼Œåº”ä¸å…¶ä»–æ¥æºæ ¸å®ä»¥ç¡®ä¿å‡†ç¡®æ€§ã€‚ | |
| **[å±é™©è¯ç‰©è”ç”¨](#Dangerous_interactions)** | |
| [æ°§åŒ–äºšæ°®](./æ°§åŒ–äºšæ°®.md) | ğŸ’” è”ç”¨å±é™© |
| [è‹¯ä¸™èƒºç±»ç‰©è´¨](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‹¯ä¸™èƒºç±»ç‰©è´¨.md) | âš ï¸ è°¨æ…è”ç”¨ |
| [MDMA](./MDMA.md) | âš ï¸ è°¨æ…è”ç”¨ |
| [å¯å¡å› ](./å¯å¡å› .md) | âš ï¸ è°¨æ…è”ç”¨ |
| [æ°¯èƒºé…®](./æ°¯èƒºé…®.md) | â›” ä¸¥ç¦è”ç”¨ |
| MXE | â›” ä¸¥ç¦è”ç”¨ |
| [å³ç¾æ²™èŠ¬](./å³ç¾æ²™èŠ¬.md) | â›” ä¸¥ç¦è”ç”¨ |
| [PCP](./PCP.md) | â›” ä¸¥ç¦è”ç”¨ |
| [é…’ç²¾](./é…’ç²¾.md) | â›” ä¸¥ç¦è”ç”¨ |
| [é˜¿ç‰‡ç±»è¯ç‰©](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/é˜¿ç‰‡ç±»è¯ç‰©.md) | â›” ä¸¥ç¦è”ç”¨ |
| Tramadol | â›” ä¸¥ç¦è”ç”¨ |
| [è‹¯äºŒæ°®å“ç±»ç‰©è´¨](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‹¯äºŒæ°®å“ç±»ç‰©è´¨.md) | â›” ä¸¥ç¦è”ç”¨ |

**Î³-ç¾ŸåŸºä¸é…¸**ï¼ˆgamma-Hydroxybutyric acidï¼Œä¹Ÿç§°ä¸º **4-ç¾ŸåŸºä¸é…¸** å’Œ **GHB**ï¼‰æ˜¯ä¸€ç§[æŠ‘åˆ¶å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md)ã€‚å®ƒä½œä¸ºä¸€ç§[ç¥ç»é€’è´¨](../æ–‡æ¡£/ç§‘å­¦ä¿¡æ¯ç´¢å¼•é¡µ.md)å¤©ç„¶å­˜åœ¨ï¼Œå¹¶ä¸”åœ¨å¤§è„‘æŸäº›åŒºåŸŸä¸­ä¹Ÿæ˜¯ GABAã€è°·æ°¨é…¸å’Œç”˜æ°¨é…¸çš„å‰ä½“ã€‚å®ƒä½œç”¨äº GHB å—ä½“ï¼Œå¹¶ä¸”æ˜¯ GABA<sub>B</sub> å—ä½“çš„å¼±æ¿€åŠ¨å‰‚ã€‚

GHB çš„é’ ç›ï¼Œå•†å“åä¸º Xyremï¼Œ[\[3\]](#cite_note-3) æ˜¯ä¸€ç§å¤„æ–¹åŠ©çœ è¯ï¼Œç”¨äºæ²»ç–—å„ç§åŒ»ç–—çŠ¶å†µï¼Œä¾‹å¦‚çŒå€’ç—‡[\[4\]](#cite_note-4)å’Œå‘ä½œæ€§ç¡ç—…æ‚£è€…çš„æ—¥é—´è¿‡åº¦å—œç¡ã€‚[\[5\]](#cite_note-5) å®ƒä¹Ÿæ›¾è¢«ç”¨äºåŒ»ç–—ç¯å¢ƒä½œä¸ºå…¨èº«éº»é†‰å‰‚ï¼Œä»¥æ²»ç–—å¤±çœ ã€ä¸´åºŠæŠ‘éƒç—‡å’Œé…’ç²¾ä¸­æ¯’ï¼Œ[\[6\]](#cite_note-6) ä»¥åŠæé«˜è¿åŠ¨è¡¨ç°ã€‚

GHB ä¹Ÿä½œä¸ºä¸€ç§å¨±ä¹æ€§ç‰©è´¨è¢«ä½¿ç”¨ï¼Œå› å…¶å…·æœ‰ç±»ä¼¼é…’ç²¾çš„æ•ˆæœã€‚è™½ç„¶å¸¸è§çš„å¨±ä¹å‰‚é‡åœ¨ 1.5 - 2.5 å…‹ä¹‹é—´ï¼Œä½† 2.5 å…‹åˆ° 5 å…‹çš„å‰‚é‡å¾ˆå¯èƒ½å¯¼è‡´åœ¨ 5 - 15 åˆ†é’Ÿå†…å…¥ç¡ï¼Œè€Œ 5 - 10 å…‹çš„å‰‚é‡å¯èƒ½å¯¼è‡´æŠ½æã€æ„è¯†ä¸§å¤±ï¼ˆæ˜è¿·çŠ¶çŠ¶æ€ï¼‰å’Œå‘•åã€‚è¶…è¿‡ 10 å…‹çš„å‰‚é‡ä¸æ­»äº¡é£é™©ç›¸å…³ã€‚[\[2\]](#cite_note-ErowidGHBVault-2) è¯·å‹¿æ··æ·†å…‹ï¼ˆgï¼‰ä¸æ¯«å‡ï¼ˆmlï¼‰ï¼ˆGHB çš„å¯†åº¦çº¦ä¸º 1.2g/ml [\[7\]](#cite_note-7)ï¼‰ã€‚å¦‚æœæœç”¨å·²ç»é¢„æ··æˆæ¶²ä½“å½¢å¼çš„ GHBï¼Œéœ€è¦æ ¼å¤–å°å¿ƒï¼Œå› ä¸ºæ— æ³•ç¡®åˆ‡çŸ¥é“æº¶æ¶²çš„æµ“åº¦ï¼ˆä¾‹å¦‚ï¼Œæ¯æ¯«å‡æº¶æ¶²ä¸­å«æœ‰å¤šå°‘å…‹ GHBï¼‰ã€‚å› æ­¤ï¼Œå»ºè®®ä½¿ç”¨è€…ä»ä½å‰‚é‡å¼€å§‹ï¼Œé€šè¿‡å°å¹…åº¦å¢åŠ å‰‚é‡æ…¢æ…¢å‘ä¸Šè°ƒæ•´ã€‚ç„¶è€Œï¼Œä¿æŒé€‚å½“çš„ç»™è¯é—´éš”å¯¹äºé¿å…æ„å¤–è¿‡é‡è‡³å…³é‡è¦ã€‚

GHB ä¸ [GBL](./GBL.md) ä¸€èµ·ï¼Œè¢«ç§°ä¸ºâ€œè¿·å¥¸è¯â€ï¼Œæ®ç§°æ˜¯è¢«ç§˜å¯†æ”¾å…¥é…’ç²¾é¥®æ–™ä¸­ã€‚\[*æ¥æºè¯·æ±‚*\] è™½ç„¶åªæœ‰éå¸¸æœ‰é™çš„è¯æ®è¡¨æ˜è¿™å®é™…ä¸Šç»å¸¸å‘ç”Ÿï¼Œä½†åœ¨æ¥å—é™Œç”Ÿäººçš„é¥®æ–™æ—¶åº”å§‹ç»ˆä¿æŒè­¦æƒ•ã€‚

## ç›®å½•

* [1 åŒ–å­¦](#Chemistry)
* [2 è¯ç†å­¦](#Pharmacology)
* [3 ä¸»è§‚æ•ˆåº”](#Subjective_effects)
    * [3.1 **èº¯ä½“æ•ˆåº”**](#Physical_effects)
    * [3.2 **è§†è§‰æ•ˆåº”**](#Visual_effects)
    * [3.3 **è®¤çŸ¥æ•ˆåº”**](#Cognitive_effects)
    * [3.4 **å¬è§‰æ•ˆåº”**](#Auditory_effects)
    * [3.5 **è¯æ•ˆæ®‹ä½™**](#After_effects)
    * [3.6 ä½“éªŒæŠ¥å‘Š](#Experience_reports)
* [4 æ¯’æ€§ä¸ä¼¤å®³æ½œåŠ›](#Toxicity_and_harm_potential)
    * [4.1 ç¥ç»æ¯’æ€§](#Neurotoxicity)
    * [4.2 è¯ç‰©è¿‡é‡](#Overdose)
    * [4.3 è€å—æ€§ä¸æˆç˜¾æ½œåŠ›](#Tolerance_and_addiction_potential)
    * [4.4 å±é™©è¯ç‰©è”ç”¨](#Dangerous_interactions)
* [5 æ³•å¾‹åœ°ä½](#Legal_status)
* [6 å¦è§](#See_also)
* [7 å¤–éƒ¨é“¾æ¥](#External_links)
* [8 å‚è€ƒæ–‡çŒ®](#References)

## åŒ–å­¦ <span id="Chemistry"></span>

GHBï¼Œå³ Î³-ç¾ŸåŸºä¸é…¸ï¼Œæ˜¯ä¸€ç§å–ä»£äº†é¢å¤–ç¾ŸåŸºçš„ç¾§é…¸ã€‚GHB åŒ…å«ä¸€ä¸ªå››ç¢³é“¾ï¼Œæœ«ç«¯ç¢³åŸå­ä¸ç¾ŸåŸºï¼ˆOH-ï¼‰ç»“åˆï¼Œå¹¶åŒé”®ç»“åˆä¸€ä¸ªæ°§åŸå­å½¢æˆç¾§åŸºå•å…ƒï¼›è¿™å°±æ˜¯ä¸é…¸ã€‚åœ¨å››ç¢³é“¾çš„å¦ä¸€ç«¯ RÎ³ ä½ç½®ï¼ŒGHB è¢«ä¸€ä¸ªç¾ŸåŸºå–ä»£ã€‚

GHB å¤©ç„¶å­˜åœ¨äºäººç±»ä¸­æ¢ç¥ç»ç³»ç»Ÿä»¥åŠè‘¡è„é…’ã€ç‰›è‚‰ã€ä¸€äº›æŸ‘æ©˜ç±»æ°´æœä»¥åŠå‡ ä¹æ‰€æœ‰åŠ¨ç‰©ä½“å†…ï¼ˆå¾®é‡ï¼‰ã€‚[\[8\]](#cite_note-8)

## è¯ç†å­¦ <span id="Pharmacology"></span>

GHB åœ¨ä¸­æ¢ç¥ç»ç³»ç»Ÿä¸­è‡³å°‘æœ‰ä¸¤ä¸ªç‹¬ç‰¹çš„ç»“åˆä½ç‚¹ã€‚[\[9\]](#cite_note-9) GHB æ˜¯æ–°è¡¨å¾çš„ GHB å—ä½“çš„[æ¿€åŠ¨å‰‚](../æ–‡æ¡£/å—ä½“æ¿€åŠ¨å‰‚.md)ï¼Œè¯¥å—ä½“å…·æœ‰å…´å¥‹æ€§ã€‚[\[10\]](#cite_note-10)[\[11\]](#cite_note-Maitre2005-11) å®ƒä¹Ÿæ˜¯ [GABA](../æ–‡æ¡£/ç§‘å­¦ä¿¡æ¯ç´¢å¼•é¡µ.md)<sub>B</sub> å—ä½“çš„å¼±[æ¿€åŠ¨å‰‚](../æ–‡æ¡£/å—ä½“æ¿€åŠ¨å‰‚.md)ï¼Œè¯¥å—ä½“å…·æœ‰æŠ‘åˆ¶æ€§ã€‚[\[11\]](#cite_note-Maitre2005-11)

ç„¶è€Œï¼Œåœ¨æ²»ç–—å‰‚é‡ä¸‹ï¼ŒGHB åœ¨å¤§è„‘ä¸­è¾¾åˆ°æ›´é«˜çš„æµ“åº¦å¹¶æ¿€æ´» [GABA](../æ–‡æ¡£/ç§‘å­¦ä¿¡æ¯ç´¢å¼•é¡µ.md)<sub>B</sub> å—ä½“ï¼Œè¿™ä¸»è¦è´Ÿè´£å…¶é•‡é™ä½œç”¨ã€‚[\[12\]](#cite_note-Dimitrijevic2005-12) GHB çš„é•‡é™ä½œç”¨ä¼šè¢« GABA<sub>B</sub> [æ‹®æŠ—å‰‚](../æ–‡æ¡£/å—ä½“æ‹®æŠ—å‰‚.md)é˜»æ–­ã€‚ç”±äº [GABA](../æ–‡æ¡£/ç§‘å­¦ä¿¡æ¯ç´¢å¼•é¡µ.md) ç³»ç»Ÿæ˜¯å¤§è„‘ä¸­æœ€å¤šäº§çš„æŠ‘åˆ¶æ€§å—ä½“ç»„ï¼Œå…¶è°ƒèŠ‚å¯¼è‡´äº† GHB å¯¹ç¥ç»ç³»ç»Ÿçš„[é•‡é™](../è¯æ•ˆ/é•‡é™.md)ï¼ˆæˆ–[æŠ—ç„¦è™‘](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md)ï¼‰ä½œç”¨ã€‚è™½ç„¶å¯¹ GHB å—ä½“çš„ç ”ç©¶æœ‰é™ï¼Œä½†æœ‰è¯æ®è¡¨æ˜åœ¨æŸäº›å¤§è„‘åŒºåŸŸæ¿€æ´» GHB å—ä½“ä¼šå¯¼è‡´[è°·æ°¨é…¸](../æ–‡æ¡£/ç§‘å­¦ä¿¡æ¯ç´¢å¼•é¡µ.md)ï¼ˆä¸»è¦çš„å…´å¥‹æ€§ç¥ç»é€’è´¨ï¼‰çš„é‡Šæ”¾ã€‚[\[13\]](#cite_note-Castelli2003-13) é€‰æ‹©æ€§æ¿€æ´» GHB å—ä½“çš„è¯ç‰©åœ¨é«˜å‰‚é‡ä¸‹ä¼šå¼•èµ·å¤±ç¥å‘ä½œï¼ŒGHB å’Œ [GABA](../æ–‡æ¡£/ç§‘å­¦ä¿¡æ¯ç´¢å¼•é¡µ.md)<sub>B</sub> æ¿€åŠ¨å‰‚ä¹Ÿæ˜¯å¦‚æ­¤ã€‚[\[13\]](#cite_note-Castelli2003-13)

GHB å—ä½“å’Œ [GABA](../æ–‡æ¡£/ç§‘å­¦ä¿¡æ¯ç´¢å¼•é¡µ.md)<sub>B</sub> å—ä½“çš„æ¿€æ´»å…±åŒå¯¼è‡´äº† GHB çš„æˆç˜¾æ€§ç‰¹å¾ã€‚GHB å¯¹[å¤šå·´èƒº](../æ–‡æ¡£/å¤šå·´èƒº.md)é‡Šæ”¾çš„å½±å“æ˜¯åŒç›¸çš„ã€‚[\[12\]](#cite_note-Dimitrijevic2005-12) è¿™æ„å‘³ç€ï¼Œè™½ç„¶ä½æµ“åº¦é€šè¿‡ GHB å—ä½“åˆºæ¿€[å¤šå·´èƒº](../æ–‡æ¡£/å¤šå·´èƒº.md)é‡Šæ”¾ï¼Œ[\[14\]](#cite_note-14) ä½†è¾ƒé«˜æµ“åº¦é€šè¿‡ [GABA](../æ–‡æ¡£/ç§‘å­¦ä¿¡æ¯ç´¢å¼•é¡µ.md)<sub>B</sub> å—ä½“æŠ‘åˆ¶[å¤šå·´èƒº](../æ–‡æ¡£/å¤šå·´èƒº.md)é‡Šæ”¾ã€‚[\[15\]](#cite_note-15) åœ¨åˆå§‹æŠ‘åˆ¶é˜¶æ®µä¹‹åï¼Œ[å¤šå·´èƒº](../æ–‡æ¡£/å¤šå·´èƒº.md)é‡Šæ”¾éšå³é€šè¿‡ GHB å—ä½“å¢åŠ ã€‚

GHB è¯±å¯¼è‰²æ°¨é…¸è¡ç”Ÿç‰©æˆ–[è‰²æ°¨é…¸](../æ–‡æ¡£/ç§‘å­¦ä¿¡æ¯ç´¢å¼•é¡µ.md)æœ¬èº«çš„ç§¯ç´¯ï¼Œå¯èƒ½æ˜¯é€šè¿‡å¢åŠ è‰²æ°¨é…¸ç©¿è¿‡è¡€è„‘å±éšœçš„è½¬è¿æ¥å®ç°çš„ã€‚GHB è¯±å¯¼çš„åˆºæ¿€å¯èƒ½å½’å› äºè‰²æ°¨é…¸å‘å¤§è„‘è½¬è¿åŠå…¶è¢«è¡€æ¸…ç´ èƒ½ç»†èƒæ‘„å–çš„å¢åŠ ã€‚ç”±äº[è¡€æ¸…ç´ èƒ½](../æ–‡æ¡£/è¡€æ¸…ç´ .md)ç³»ç»Ÿå¯èƒ½æ¶‰åŠç¡çœ ã€æƒ…ç»ªå’Œç„¦è™‘çš„è°ƒèŠ‚ï¼Œé«˜å‰‚é‡ GHB å¯¹è¯¥ç³»ç»Ÿçš„åˆºæ¿€å¯èƒ½æ¶‰åŠ GHB ç»™è¯å¼•èµ·æŸäº›ç¥ç»è¯ç†å­¦äº‹ä»¶ã€‚

è¿™äº›å‘ç°å¯èƒ½è§£é‡Šäº† GHB é•‡é™å’Œå…´å¥‹ç‰¹æ€§çš„çŸ›ç›¾æ··åˆï¼Œä»¥åŠä½¿ç”¨ GHB ä½œä¸ºåŠ©çœ å‰‚çš„äººæŠ¥å‘Šçš„æ‰€è°“â€œåå¼¹â€æ•ˆåº”ï¼Œå³ä»–ä»¬åœ¨æ•°å°æ—¶çš„ GHB è¯±å¯¼çš„æ·±åº¦ç¡çœ åçªç„¶é†’æ¥ã€‚éšç€æ—¶é—´çš„æ¨ç§»ï¼Œç³»ç»Ÿä¸­çš„ GHB æµ“åº¦é™ä½åˆ°æ˜¾è‘—æ¿€æ´» [GABA](../æ–‡æ¡£/ç§‘å­¦ä¿¡æ¯ç´¢å¼•é¡µ.md)<sub>B</sub> å—ä½“çš„é˜ˆå€¼ä»¥ä¸‹ï¼Œå¹¶ä¸»è¦æ¿€æ´» GHB å—ä½“ï¼Œä»è€Œå¯¼è‡´æ¸…é†’ã€‚

## ä¸»è§‚æ•ˆåº” <span id="Subjective_effects"></span>

***å…è´£å£°æ˜ï¼š** ä¸‹åˆ—æ•ˆåº”å¼•ç”¨è‡ª [***ä¸»è§‚æ•ˆåº”ç´¢å¼•***](../æ–‡æ¡£/ç§‘å­¦ä¿¡æ¯ç´¢å¼•é¡µ.md) (**SEI**)ï¼Œè¿™æ˜¯ä¸€ä¸ªåŸºäºè½¶äº‹ç”¨æˆ·æŠ¥å‘Šå’Œ [PsychonautWiki](https://psychonautwiki.org) è´¡çŒ®è€…ä¸ªäººåˆ†æçš„å¼€æ”¾ç ”ç©¶æ–‡çŒ®ã€‚å› æ­¤ï¼Œåº”ä»¥å¥åº·çš„æ€€ç–‘æ€åº¦çœ‹å¾…è¿™äº›å†…å®¹ã€‚*

*åŒæ ·å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œè¿™äº›æ•ˆåº”å¹¶ä¸ä¸€å®šä¼šä»¥å¯é¢„æµ‹æˆ–å¯é çš„æ–¹å¼å‘ç”Ÿï¼Œå°½ç®¡é«˜å‰‚é‡æ›´å¯èƒ½è¯±å‘å…¨æ–¹ä½çš„æ•ˆåº”ã€‚åŒæ ·ï¼Œ**ä¸è‰¯ååº”**éšç€å‰‚é‡çš„å¢åŠ è€Œå˜å¾—è¶Šæ¥è¶Šå¯èƒ½ï¼Œå¹¶ä¸”å¯èƒ½åŒ…æ‹¬**æˆç˜¾ã€ä¸¥é‡ä¼¤å®³æˆ–æ­»äº¡** â˜ ã€‚*

### **èº¯ä½“æ•ˆåº”** <span id="Physical_effects"></span>

*   **[åˆºæ¿€](../è¯æ•ˆ/åˆºæ¿€.md)** & **[é•‡é™](../è¯æ•ˆ/é•‡é™.md)** - åœ¨è¾ƒä½å‰‚é‡ä¸‹ï¼ŒGHB å…·æœ‰èº¯ä½“å…´å¥‹æ€§ï¼Œé¼“åŠ±è¿åŠ¨å’Œæ¸…é†’ã€‚ç„¶è€Œï¼Œåœ¨è¾ƒé«˜å‰‚é‡ä¸‹ï¼Œå®ƒä¼šäº§ç”Ÿèº¯ä½“é•‡é™ä½œç”¨ï¼Œå¯¼è‡´ç¡çœ å’Œå—œç¡ã€‚
*   **[å‘¼å¸æŠ‘åˆ¶](../è¯æ•ˆ/å‘¼å¸æŠ‘åˆ¶.md)** - åœ¨ GHB è¿‡é‡çš„æƒ…å†µä¸‹ï¼Œè®¸å¤šäººæŠ¥å‘Šç»å†å¼‚å¸¸çš„å‘¼å¸æ¨¡å¼ï¼Œç‰¹å¾æ˜¯å‘¼å¸é€æ¸åŠ æ·±ï¼Œæœ‰æ—¶åŠ å¿«ï¼Œç„¶åé€æ¸å‡æ…¢ï¼Œå¯¼è‡´å‘¼å¸æš‚æ—¶åœæ­¢ï¼Œç§°ä¸ºå‘¼å¸æš‚åœã€‚
*   **[è‚Œè‚‰æ¾å¼›](../è¯æ•ˆ/è‚Œè‚‰æ¾å¼›.md)** - GHB å¼•èµ·æ·±åˆ»çš„è‚Œè‚‰æ¾å¼›ï¼Œç±»ä¼¼äºä½†æ¯”[è‹¯äºŒæ°®å“ç±»ç‰©è´¨](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‹¯äºŒæ°®å“ç±»ç‰©è´¨.md)å’Œ[é…’ç²¾](./é…’ç²¾.md)äº§ç”Ÿçš„æ¾å¼›æ›´å¼ºçƒˆã€‚è¿™ç§è‚Œè‚‰æ¾å¼›ä¼´éšç€è¿åŠ¨æ§åˆ¶çš„æ™®éä¸§å¤±ï¼Œè¿™å¯èƒ½ä¼šå¢åŠ ä½¿ç”¨è€…èº«ä½“å—ä¼¤çš„é£é™©ã€‚
*   **[è„±æ°´](../è¯æ•ˆ/è„±æ°´.md)**
*   **[å¤´æ™•](../è¯æ•ˆ/å¤´æ™•.md)** - å¤´æ™•æ˜¯ GHB çš„å¸¸è§å‰¯ä½œç”¨ï¼Œå¯åœ¨æ­£å¸¸å¨±ä¹å‰‚é‡ä¸‹å‘ç”Ÿã€‚ä½¿ç”¨è€…ä¹Ÿå¯èƒ½çªç„¶æ„Ÿåˆ°å¤´æ™•æˆ–æ™•å¥ï¼Œå¹¶æœ‰å¼ºçƒˆçš„èººä¸‹å†²åŠ¨ã€‚ä¿—ç§°â€œå¤©æ—‹åœ°è½¬ï¼ˆthe spinsï¼‰â€ã€‚
*   **[è¿åŠ¨æ§åˆ¶ä¸§å¤±](../è¯æ•ˆ/è¿åŠ¨æ§åˆ¶ä¸§å¤±.md)**
*   **[æ¶å¿ƒ](../è¯æ•ˆ/æ¶å¿ƒ.md)**
*   **[æµæ¶å¢åŠ ](../è¯æ•ˆ/æµæ¶å¢åŠ .md)** - æµæ¶å¢åŠ éå¸¸å¸¸è§ã€‚
*   **[èƒƒç—‰æŒ›](../è¯æ•ˆ/èƒƒç—‰æŒ›.md)**
*   **[è‚Œè‚‰ç—‰æŒ›](../è¯æ•ˆ/è‚Œè‚‰ç—‰æŒ›.md)**
*   **[çœ¼çƒæ»‘åŠ¨](../è¯æ•ˆ/çœ¼çƒæ»‘åŠ¨.md)**
*   **[ç³å­”æ‰©å¤§](../è¯æ•ˆ/ç³å­”æ‰©å¤§.md)**
*   **[è¡€ç®¡æ‰©å¼ ](../è¯æ•ˆ/è¡€ç®¡æ‰©å¼ .md)**
*   **[å¤´ç—›](../è¯æ•ˆ/å¤´ç—›.md)**
*   **[ç™«ç—«å‘ä½œ](../è¯æ•ˆ/ç™«ç—«å‘ä½œ.md)** - æé«˜å‰‚é‡çš„ GHB å§‹ç»ˆä¼šå¯¼è‡´æŠ½æã€‚
*   **[æ€§é«˜æ½®æŠ‘åˆ¶](../è¯æ•ˆ/æ€§é«˜æ½®æŠ‘åˆ¶.md)** - å¯èƒ½åœ¨é«˜å‰‚é‡æˆ–å¤šæ¬¡é‡å¤ç»™è¯æ—¶å‘ç”Ÿã€‚

### **è§†è§‰æ•ˆåº”** <span id="Visual_effects"></span>

*   **[è§†è§‰é”åº¦æŠ‘åˆ¶](../è¯æ•ˆ/è§†è§‰é”åº¦æŠ‘åˆ¶.md)**
*   **[æ®‹å½±](../è¯æ•ˆ/æ®‹å½±.md)**
*   **[é€è§†æ‰­æ›²](../è¯æ•ˆ/è§†è§‰æ‰­æ›².md)**
*   **[æ·±åº¦æ„ŸçŸ¥æ‰­æ›²](../è¯æ•ˆ/æ·±åº¦æ„ŸçŸ¥æ‰­æ›².md)**
*   **[æ™¯è‰²åˆ‡ç‰‡](../è¯æ•ˆ/è§†è§‰æ•ˆåº”.md)**

### **è®¤çŸ¥æ•ˆåº”** <span id="Cognitive_effects"></span>

*   **[å—œç¡](../è¯æ•ˆ/é•‡é™.md)** & **[æ¸…é†’](../è¯æ•ˆ/åˆºæ¿€.md)** - åœ¨æä½å‰‚é‡ä¸‹ï¼ŒGHB ä¼šè®©äººæ„Ÿåˆ°ç–²å€¦ï¼Œè€Œä¸­ç­‰å‰‚é‡ä¸»è¦ä¿ƒè¿›æ¸…é†’ã€‚é«˜å‰‚é‡ä¼šå¯¼è‡´æåº¦å—œç¡çš„æ„Ÿè§‰ã€‚
*   **[åˆ†ææŠ‘åˆ¶](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md)**
*   **[ç„¦è™‘æŠ‘åˆ¶](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md)**
*   **[è®¤çŸ¥æ¬£å¿«](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md)** - GHB äº§ç”Ÿå¼ºçƒˆçš„æ¬£å¿«çŠ¶æ€ï¼Œå¯ä¸[å¯å¡å› ](./å¯å¡å› .md)ã€[MDMA](./MDMA.md)å’Œ[é˜¿ç‰‡ç±»è¯ç‰©](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/é˜¿ç‰‡ç±»è¯ç‰©.md)ç›¸åª²ç¾ã€‚å› ä¸ºè¿™ä¸ªåŸå› ï¼Œå®ƒæœ‰æ—¶è¢«ç§°ä¸ºâ€œæ¶²ä½“æ‘‡å¤´ä¸¸â€ã€‚å®ƒé€šå¸¸è¢«æè¿°ä¸ºé…’ç²¾çš„æ›´æ¬£å¿«å’Œæ›´å»æŠ‘åˆ¶çš„ç‰ˆæœ¬ã€‚è™½ç„¶è¿™å¯èƒ½æ˜¯å‡†ç¡®çš„ï¼Œä½†ä¹Ÿæ›´å®¹æ˜“è¿‡é‡ã€‚
*   **[å¼ºè¿«æ€§é‡å¤ç»™è¯](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md)** - ç”±äºå…¶æŒç»­æ—¶é—´çŸ­å’Œåå¼¹ç„¦è™‘ï¼Œè¿™ç§æƒ…å†µæ¯”è¾ƒæ™®éã€‚
*   **[åˆ›é€ åŠ›å¢å¼º](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md)** - åˆ›é€ åŠ›å¢å¼ºåœ¨ä½è‡³ä¸­ç­‰å‰‚é‡ä¸‹æœ€ä¸ºæ˜æ˜¾ã€‚
*   **[å»æŠ‘åˆ¶](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md)** - GHB çš„ç¤¾äº¤å’Œè¡Œä¸ºå»æŠ‘åˆ¶æå…¶å¼ºå¤§ï¼Œæˆ–è®¸æ˜¯å…¶æœ€æ˜¾è‘—çš„ç‰¹å¾ã€‚ä½¿ç”¨è€…æ›´å®¹æ˜“è¡¨ç°å‡ºå†³ç­–èƒ½åŠ›å—æŸï¼Œå¹¶ä»äº‹å±é™©æ´»åŠ¨ï¼Œå¦‚æ— ä¿æŠ¤æ€§è¡Œä¸ºæˆ–ä¸å®‰å…¨çš„ç‰©è´¨è”ç”¨ã€‚å»ºè®®ä½¿ç”¨è€…ä»…åœ¨å®‰å…¨çš„ç¯å¢ƒä¸­ï¼Œä¸ä»–ä»¬ä¿¡ä»»ä¸”ä¸ä¼šåˆ©ç”¨å…¶è„†å¼±çŠ¶æ€çš„äººä¸€èµ·ä½¿ç”¨ GHBã€‚
*   **[æ¢¦å¢ƒå¢å¼º](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/ä¿ƒæ¢¦å‰‚.md)** - GHB å¯¹æ¢¦å¢ƒçš„å›å¿†å’Œç”ŸåŠ¨æ€§æœ‰éå¸¸æ˜¾è‘—çš„å½±å“ã€‚ç›¸åï¼Œåœè¯å¯èƒ½ä¼šå¯¼è‡´å™©æ¢¦ã€‚æ­¤å¤–ï¼ŒGBL ä¸­æ¯’å¯èƒ½å¯¼è‡´äººçœ‹åˆ°è‡ªå·±çš„æ¢¦å¢ƒæ˜¾ç°ï¼Œç±»ä¼¼äº[æ¸…é†’è¯±å¯¼æ¸…æ˜æ¢¦](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/ä¿ƒæ¢¦å‰‚.md)ï¼ˆWILDï¼‰ä»¥åŠæ¸…é†’å’Œåšæ¢¦å¹¶å­˜çš„çŠ¶æ€ã€‚
*   **[å…±æƒ…ã€æƒ…æ„Ÿå’Œç¤¾äº¤èƒ½åŠ›å¢å¼º](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md)** - GHB è¡¨ç°å‡ºå¼ºçƒˆçš„[å…±æƒ…å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…±æƒ…å‰‚.md)æ•ˆåº”ï¼Œè™½ç„¶æ¯”[MDMA](./MDMA.md)å¼±ï¼Œä½†ä»ç„¶æ˜¾è‘—ä¸”å®šä¹‰æ˜ç¡®ã€‚
*   **[æ²‰æµ¸æ„Ÿå¢å¼º](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md)**
*   **[æ€§æ¬²å¢å¼º](../è¯æ•ˆ/æ€§æ¬²å¢å¼º.md)** - æ®æŠ¥é“ï¼ŒGBL äº§ç”Ÿçš„æ€§æ¬²å¢åŠ å°‘äº GHBã€‚
*   **[éŸ³ä¹æ¬£èµå¢å¼º](../è¯æ•ˆ/å¬è§‰æ•ˆåº”.md)**
*   **[å†…çœ](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md)**
*   **[å›æ˜¥æ„Ÿ](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md)**
*   **[æ˜“æ„Ÿæ€§å¢å¼º](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md)**
*   **[è®°å¿†æŠ‘åˆ¶](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md)**
    *   **[å¥å¿˜](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md)**
*   **[åŠ¨åŠ›å¢å¼º](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md)** & **[åŠ¨åŠ›æŠ‘åˆ¶](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md)** - ä¸å…¶ä»–å¹¶å­˜æ•ˆåº”ä¸€æ ·ï¼Œä¸­ç­‰å‰‚é‡å¯å¯¼è‡´åŠ¨åŠ›å¢å¼ºï¼Œè€Œé«˜å‰‚é‡é€šå¸¸å¯¼è‡´å—œç¡ã€‚
*   **[ç©ºé—´è¿·å¤±](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md)** - åœ¨é»‘æš—åŒºåŸŸéå¸¸å¸¸è§ã€‚
*   **[æ€ç»´åŠ é€Ÿ](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md)** æˆ– **[æ€ç»´å‡é€Ÿ](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md)** - ä½è‡³ä¸­ç­‰å‰‚é‡ä¸»è¦æ˜¯åˆºæ¿€æ€§çš„ï¼Œè®©äººå‘ç°è‡ªå·±ä¸æ–­äº§ç”Ÿæƒ³æ³•ã€‚

### **å¬è§‰æ•ˆåº”** <span id="Auditory_effects"></span>

*   **[è€³é¸£](https://en.wikipedia.org/wiki/Tinnitus)**
*   **[å¬è§‰æ‰­æ›²](../è¯æ•ˆ/å¬è§‰æ•ˆåº”.md)**

### **è¯æ•ˆæ®‹ä½™** <span id="After_effects"></span>

*   **[åå¼¹ç„¦è™‘](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md)** - åå¼¹ç„¦è™‘æ˜¯åƒ GHB è¿™æ ·çš„[æŠ—ç„¦è™‘](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md)ç‰©è´¨å¸¸è§çš„æ•ˆåº”ã€‚è¿™åŠ ä¸Š GHB ä½œç”¨æ—¶é—´çŸ­ï¼Œå¯èƒ½å¯¼è‡´å¼ºè¿«æ€§é‡å¤ç»™è¯ã€‚

### ä½“éªŒæŠ¥å‘Š <span id="Experience_reports"></span>

ç›®å‰æˆ‘ä»¬çš„[ä½“éªŒç´¢å¼•](../æ–‡æ¡£/ç§‘å­¦ä¿¡æ¯ç´¢å¼•é¡µ.md)ä¸­æ²¡æœ‰æè¿°è¯¥åŒ–åˆç‰©æ•ˆåº”çš„è½¶äº‹æŠ¥å‘Šã€‚å…¶ä»–çš„ä½“éªŒæŠ¥å‘Šå¯ä»¥åœ¨è¿™é‡Œæ‰¾åˆ°ï¼š

* [Erowid Experience Vaults: GHB](https://www.erowid.org/experiences/subs/exp_GHB.shtml)

## æ¯’æ€§ä¸ä¼¤å®³æ½œåŠ› <span id="Toxicity_and_harm_potential"></span>

[![](../æ–‡ä»¶/HarmCausedByDrugsTable.svg)](../æ–‡ä»¶/HarmCausedByDrugsTable.svg)

æ¥è‡ª 2010 å¹´ [DrugScience](https://www.drugscience.org.uk/) ç ”ç©¶çš„è¡¨æ ¼ï¼Œæ ¹æ®è¯ç‰©å±å®³ä¸“å®¶çš„é™ˆè¿°å¯¹å„ç§è¯ç‰©ï¼ˆåˆæ³•å’Œéæ³•ï¼‰è¿›è¡Œæ’åã€‚GHB è¢«å‘ç°æ˜¯æ•´ä½“å±é™©æ€§ç¬¬ä¹é«˜çš„è¯ç‰©ã€‚[\[16\]](#cite_note-Nutt_2010-16)

[![](../æ–‡ä»¶/Harmchart.png)](../æ–‡ä»¶/Harmchart.png)

æ˜¾ç¤º GHB ç›¸å¯¹èº«ä½“ä¼¤å®³ã€ç¤¾ä¼šä¼¤å®³å’Œä¾èµ–æ€§çš„é›·è¾¾å›¾[\[17\]](#cite_note-17)

å½“è´Ÿè´£ä»»åœ°æˆ–åœ¨åŒ»ç–—ä¸Šä½¿ç”¨æ—¶ï¼ŒGHB è¢«è®¤ä¸ºæ˜¯å®‰å…¨ä¸”æ— æ¯’çš„ç‰©è´¨ã€‚[åŠæ•°è‡´æ­»é‡ï¼ˆLD50ï¼‰](../æ–‡æ¡£/ç»™è¯å‰‚é‡.md)é«˜äºæ´»æ€§å‰‚é‡ï¼Œæ²¡æœ‰æ€¥æ€§æ¯’æ€§çš„å±é™©ã€‚ç„¶è€Œï¼Œå½“ä½œä¸ºå¨±ä¹æ€§è¯ç‰©ä½¿ç”¨æˆ–æ»¥ç”¨æ—¶ï¼Œå®ƒå¯èƒ½ä¼šå˜å¾—å±é™©ã€‚æœ‰è®¸å¤šæ¥è‡ªå¨±ä¹ä½¿ç”¨è€…çš„è´Ÿé¢æŠ¥å‘Šï¼Œä»–ä»¬ç»å†äº†è¯ç‰©è¿‡é‡ã€å°† GHB ä¸é…’ç²¾æˆ–å…¶ä»–è¯ç‰©æ··åˆä½¿ç”¨ï¼Œæˆ–æ„å¤–åœ°æ„å¤–æœç”¨äº†å‰‚é‡ã€‚[\[18\]](#cite_note-18)

ä¸€ä»½å‡ºç‰ˆç‰©è°ƒæŸ¥äº† 226 ä¾‹å½’å› äº GHB çš„æ­»äº¡ã€‚[\[19\]](#cite_note-19) 71 ä¾‹æ­»äº¡ï¼ˆ34%ï¼‰ç”±å•ç‹¬ä½¿ç”¨ GHB å¼•èµ·ï¼Œè€Œå…¶ä»–æ­»äº¡æ˜¯ç”±ä¸é…’ç²¾æˆ–å…¶ä»–è¯ç‰©ç›¸äº’ä½œç”¨å¼•èµ·çš„[å‘¼å¸æŠ‘åˆ¶](../è¯æ•ˆ/å‘¼å¸æŠ‘åˆ¶.md)ã€‚

ä½œä¸ºèƒ½é‡ä»£è°¢çš„å†…æºæ€§è°ƒèŠ‚å‰‚å’Œå¤©ç„¶ç¥ç»é€’è´¨ï¼ŒGHB ä¸ºå¤§è„‘å’Œå™¨å®˜æ‰€ç†ŸçŸ¥ï¼Œè¿™äº›å™¨å®˜ä¹ æƒ¯äºå…¶æ•ˆåº”å¹¶æ‹¥æœ‰é«˜æ•ˆçš„ç³»ç»Ÿæ¥å®‰å…¨ä»£è°¢å®ƒã€‚è¯¥ç‰©è´¨åœ¨ 2-4 å°æ—¶å†…æ¶ˆé™¤ï¼ˆå³æ¢å¤åˆ°åŸºçº¿æ°´å¹³ï¼‰ï¼Œå³ä½¿è¿ç»­ä¸€å‘¨æ¯æ—¥ä¸¤æ¬¡ç»™è¯ä¹Ÿæ˜¯å¦‚æ­¤ã€‚[\[20\]](#cite_note-20) åœ¨ä¸€é¡¹æ¬§æ´²ç ”ç©¶ä¸­ï¼Œåœ¨å‡ å¹´çš„å®šæœŸå¨±ä¹æ€§ä½¿ç”¨åæœªæŠ¥å‘Šä¸è‰¯ååº”ã€‚[\[21\]](#cite_note-21)

ç”±äºå‚¨å­˜æ–¹æ³•ä¸å½“ï¼Œä¹Ÿå‘ç”Ÿè¿‡æ„å¤–æ‘„å…¥ GHB çš„æƒ…å†µã€‚å¦‚æœå°† GHB æ”¾å…¥é€æ˜æ¶²ä½“ã€ç»ç’ƒæ¯æˆ–ç“¶å­ä¸­ï¼Œå¾ˆå®¹æ˜“è¢«è¯¯è®¤ä¸ºæ˜¯æ°´ã€‚å»ºè®®ç”¨ä¹¦é¢å½¢å¼æ¸…æ¥šåœ°æ ‡è®°æ‚¨çš„ GHBï¼Œå¹¶ç”¨è“è‰²é£Ÿç”¨è‰²ç´ å°†æ¶²ä½“æŸ“è‰²ï¼Œä½¿å…¶ä¸å†åƒå¯é¥®ç”¨çš„é¥®æ–™ã€‚è¿˜å»ºè®®å°†æ‚¨çš„ GHB å­˜æ”¾åœ¨æ²¡æœ‰äººä¼šé¥®ç”¨çš„å®¹å™¨ä¸­ã€‚

GHB è¿˜å…·æœ‰è…èš€æ€§ï¼Œå»ºè®®ç”¨éé…’ç²¾æ¶²ä½“ä»¥è‡³å°‘ 1:100ml çš„æ¯”ä¾‹ç¨€é‡Šï¼Œå¦‚æœä¸è¿™æ ·åšï¼Œå¯èƒ½ä¼šå¯¼è‡´è‚ é“å’Œå£è…”ç¼ä¼¤ã€‚[\[1\]](https://sidekicks.berlin/en/ghb-gbl/#beratung)

å¼ºçƒˆå»ºè®®åœ¨ä½¿ç”¨æ­¤ç‰©è´¨æ—¶é‡‡å–[ä¼¤å®³å‡å°‘æªæ–½](../æ–‡æ¡£/è´Ÿè´£ä»»çš„ç”¨è¯ç´¢å¼•é¡µ.md)ã€‚

### ç¥ç»æ¯’æ€§ <span id="Neurotoxicity"></span>

2022 å¹´çš„ä¸€é¡¹ç»¼è¿°[\[22\]](#cite_note-22)æ¯”è¾ƒäº† 43 é¡¹å…³äº GHB è¯±å¯¼çš„äººç±»å’ŒåŠ¨ç‰©è®¤çŸ¥éšœç¢çš„ç ”ç©¶ã€‚åˆ†æè¡¨æ˜ï¼Œé€‚åº¦æˆ–ä¸´åºŠä½¿ç”¨å¯èƒ½å¯¼è‡´æ€¥æ€§è®¤çŸ¥éšœç¢ã€‚ä½è‡³ 10mg/kg çš„å‰‚é‡åï¼Œå·¥ä½œè®°å¿†ã€çŸ­æœŸè®°å¿†å—æŸï¼Œè®¤çŸ¥ä»»åŠ¡è¡¨ç°å—æŸï¼Œä½†è¿™äº›å½±å“ä¼¼ä¹æ˜¯æš‚æ—¶çš„ã€‚ç›¸åï¼Œä¸€é¡¹ç ”ç©¶å‘ç°ï¼Œ20mg/kg çš„å‰‚é‡æ”¹å–„äº†ç¤¾äº¤å’Œéç¤¾äº¤è®¤çŸ¥ï¼Œä½†ä¸å½±å“åŸºç¡€è®¤çŸ¥åŠŸèƒ½ï¼Œå¦‚è§†è§‰æˆ–è¯­è¨€è®°å¿†å›å¿†ã€‚ç„¶è€Œï¼Œé•¿æœŸå¤§é‡ä½¿ç”¨ GHBï¼Œç‰¹åˆ«æ˜¯å¦‚æœä¼´æœ‰ GHB è¯±å¯¼çš„æ˜è¿·ï¼Œä¼¼ä¹ä¼šå¯¼è‡´é•¿æœŸçš„è®¤çŸ¥éšœç¢ï¼Œå¹¶ä¸”å¯èƒ½å…·æœ‰ç¥ç»æ¯’æ€§ã€‚

åœ¨å¤šé¡¹ç ”ç©¶ä¸­ï¼Œå‘ç°é•¿æœŸç»™è¯ GHB ä¼šæŸå®³å¤§é¼ çš„ç©ºé—´è®°å¿†ã€å·¥ä½œè®°å¿†ã€å­¦ä¹ å’Œè®°å¿†ã€‚[\[23\]](#cite_note-23)[\[24\]](#cite_note-24)[\[25\]](#cite_note-25)[\[26\]](#cite_note-26) è¿™äº›å½±å“ä¸å¤§è„‘çš®å±‚åŠå¯èƒ½å…¶ä»–åŒºåŸŸçš„ [NMDA å—ä½“](../æ–‡æ¡£/å—ä½“æ¿€åŠ¨å‰‚.md)è¡¨è¾¾å‡å°‘æœ‰å…³ã€‚[\[27\]](#cite_note-27)

ä¸€é¡¹ç ”ç©¶å‘ç°ï¼Œå¯¹å¤§é¼ é‡å¤ç»™äºˆ GHB 15 å¤©ï¼Œæµ·é©¬ä½“å’Œå‰é¢å¶çš®å±‚å†…çš„ç¥ç»å…ƒå’Œéç¥ç»å…ƒç»†èƒæ•°é‡æ€¥å‰§å‡å°‘ã€‚å‰‚é‡ä¸º 10 mg/kg GHB æ—¶ï¼Œæµ·é©¬åŒºåŸŸå‡å°‘äº† 61%ï¼Œå‰é¢å¶çš®å±‚å‡å°‘äº† 32%ï¼Œè€Œåœ¨ 100 mg/kg æ—¶ï¼Œåˆ†åˆ«å‡å°‘äº† 38% å’Œ 9%ã€‚è¯¥è®ºæ–‡å±•ç¤ºäº†å…³äºç¥ç»å…ƒä¸¢å¤±çš„çŸ›ç›¾æ•ˆåº”ï¼Œè¾ƒä½å‰‚é‡ï¼ˆ10 mg/kgï¼‰äº§ç”Ÿæœ€å¤§çš„ç¥ç»æ¯’æ€§ï¼Œè€Œè¾ƒé«˜å‰‚é‡ï¼ˆ100 mg/kgï¼‰äº§ç”Ÿçš„ç¥ç»æ¯’æ€§è¾ƒå°ã€‚

### è¯ç‰©è¿‡é‡ <span id="Overdose"></span>

ä¸ºäº†é¿å… GHB å¯èƒ½çš„è¿‡é‡ï¼Œé‡è¦çš„æ˜¯ä»ä½å‰‚é‡å¼€å§‹ï¼Œé€šè¿‡å°å¹…åº¦å¢åŠ å‰‚é‡æ…¢æ…¢å‘ä¸Šè°ƒæ•´ã€‚è™½ç„¶å¸¸è§çš„å¨±ä¹å‰‚é‡æ˜¯ 3gï¼Œä½† 5g - 10g çš„å‰‚é‡å¯èƒ½å¯¼è‡´æŠ½æã€æ„è¯†ä¸§å¤±å’Œå‘•åã€‚è¶…è¿‡ 10 å…‹çš„å‰‚é‡ä¸æ­»äº¡é£é™©ç›¸å…³ã€‚[\[2\]](#cite_note-ErowidGHBVault-2) è¿˜å¿…é¡»è€ƒè™‘åˆ°çŸ¥é“äº§å“çº¯åº¦çš„é¢å¤–å›°éš¾ï¼ˆé™¤äº†å…¶ä»–é—®é¢˜ï¼Œå¦‚å…¶å¸æ¹¿æ€§å¯èƒ½ä¼šé™ä½æº¶æ¶²ä¸­ GHB çš„æµ“åº¦ï¼Œè¿™æ˜¯åœ¨éæ³•å¸‚åœºä¸Šä¹°å–çš„å¸¸è§å½¢å¼ï¼‰ã€‚è¿™ä½¿å¾—å³ä½¿æ˜¯ç»éªŒä¸°å¯Œçš„ä½¿ç”¨è€…ä¹Ÿå¾ˆéš¾æ­£ç¡®ç»™è¯ã€‚[\[28\]](#cite_note-28)

### è€å—æ€§ä¸æˆç˜¾æ½œåŠ› <span id="Tolerance_and_addiction_potential"></span>

[![](../æ–‡ä»¶/GHBwithdrawal2.png)](../æ–‡ä»¶/GHBwithdrawal2.png)

æ­¤è¡¨æ¯”è¾ƒäº† GHBã€[è‹¯äºŒæ°®å“ç±»ç‰©è´¨](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‹¯äºŒæ°®å“ç±»ç‰©è´¨.md)å’Œ[é…’ç²¾](./é…’ç²¾.md)çš„æˆ’æ–­ç—‡çŠ¶ã€‚[\[29\]](#cite_note-GHB-29)

GHB å…·æœ‰ä¸­åº¦åˆ°é«˜åº¦çš„èº«ä½“æˆç˜¾æ€§å’Œä¸­åº¦çš„å¿ƒç†æˆç˜¾æ€§ã€‚å¦‚æœçªç„¶åœè¯ï¼Œé¢‘ç¹ä½¿ç”¨ GHB ä¼šå¼•èµ·ä¸å…¶ä»–[æŠ‘åˆ¶å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md)å¦‚[é…’ç²¾](./é…’ç²¾.md)å’Œ[è‹¯äºŒæ°®å“ç±»ç‰©è´¨](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‹¯äºŒæ°®å“ç±»ç‰©è´¨.md)ç›¸ä¼¼çš„æˆ’æ–­ç—‡çŠ¶ã€‚[\[30\]](#cite_note-30)[\[31\]](#cite_note-31) è¿™äº›ç—‡çŠ¶ä¼¼ä¹å–å†³äºå‰‚é‡å’Œä½¿ç”¨è¯ç‰©çš„æ—¶é—´é•¿åº¦ã€‚è½»åº¦è‡³ä¸­åº¦ä½¿ç”¨è€…ç»å¸¸ç»å†ç„¦è™‘ã€å¤±çœ ã€ç¡çœ ç›¸å…³é—®é¢˜å’Œéœ‡é¢¤ï¼Œè€Œå¤§é‡ä½¿ç”¨ä¼šå¯¼è‡´ä¸¥é‡çš„æˆ’æ–­ç—‡çŠ¶ï¼Œå¦‚è°µå¦„ã€ç²¾ç¥ç—…å’Œå¹»è§‰ã€‚[\[32\]](#cite_note-32)[\[29\]](#cite_note-GHB-29)

å½“åŒ»ç–—ä½¿ç”¨ GHBï¼ˆæ¯å¤©ä¸¤å‰‚è¯ç”¨å‰‚é‡ï¼Œé—´éš”å››å°æ—¶ï¼‰æ—¶ï¼Œå‡ ä¹ä¸ä¼šäº§ç”Ÿä¾èµ–æ€§ï¼Œè€Œä½¿ç”¨ GHB è¶Šé¢‘ç¹ï¼Œå…¶å¯¼è‡´ä¾èµ–å’Œæˆ’æ–­ç—‡çŠ¶çš„å¯èƒ½æ€§å‘ˆæŒ‡æ•°çº§å¢åŠ ã€‚[\[33\]](#cite_note-33)

è™½ç„¶æœ‰æŠ¥é“ç§°å›  GHB æˆ’æ–­è€Œæ­»äº¡ï¼Œä½†æŠ¥å‘Šå°šæ— å®šè®ºï¼Œéœ€è¦è¿›ä¸€æ­¥ç ”ç©¶ã€‚[\[34\]](#cite_note-34)

è¿ç»­ä½¿ç”¨å‡ å¤©åï¼Œå¯¹é•‡é™å‚¬çœ ä½œç”¨çš„è€å—æ€§å°±ä¼šäº§ç”Ÿã€‚åœè¯åï¼Œè€å—æ€§åœ¨ 7 - 14 å¤©å†…æ¢å¤åˆ°åŸºçº¿æ°´å¹³ã€‚åœ¨ç¨³å®šç»™è¯å‡ å‘¨æˆ–æ›´é•¿æ—¶é—´åçªç„¶åœæ­¢ä½¿ç”¨å¯èƒ½ä¼šå‡ºç°æˆ’æ–­ç—‡çŠ¶æˆ–åå¼¹ç—‡çŠ¶ï¼Œå¹¶ä¸”å¯èƒ½éœ€è¦é€æ¸å‡å°‘å‰‚é‡ä»¥å°½é‡å‡å°‘æˆ’æ–­å¼•èµ·çš„ç¥ç»æ¯’æ€§ã€‚æœ‰äººæå‡º GHBï¼Œç‰¹åˆ«æ˜¯ GBL å¯ä»¥å¯¼è‡´æ¯”é•¿æ•ˆæŠ‘åˆ¶å‰‚å¿«å¾—å¤šçš„ä¾èµ–é€Ÿåº¦ã€‚

GHB ä¸ [1,4-ä¸äºŒé†‡](../æ–‡æ¡£/è¯ç‰©å‰è¯.md) å’Œ [GBL](./GBL.md) è¡¨ç°å‡ºäº¤å‰è€å—æ€§ï¼Œå› ä¸ºè¿™äº›ç‰©è´¨å……å½“ GHB çš„[å‰è¯](../æ–‡æ¡£/è¯ç‰©å‰è¯.md)ã€‚åœ¨å¤§é¼ ä¸­å·²æ˜¾ç¤ºä¸[é…’ç²¾](./é…’ç²¾.md)å’Œ[å·´æ°¯èŠ¬](./å·´æ°¯èŠ¬.md)çš„äº¤å‰è€å—æ€§ï¼Œ[\[35\]](#cite_note-35)[\[36\]](#cite_note-36) å¹¶ä¸”ä¸å…¶ä»– GABA<sub>B</sub> æ¿€åŠ¨å‰‚ä¹Ÿå¯èƒ½å­˜åœ¨äº¤å‰è€å—æ€§ã€‚

### å±é™©è¯ç‰©è”ç”¨ <span id="Dangerous_interactions"></span>

***è­¦å‘Šï¼š*** *è®¸å¤šç²¾ç¥æ´»æ€§ç‰©è´¨å•ç‹¬ä½¿ç”¨æ—¶ç›¸å¯¹å®‰å…¨ï¼Œä½†å½“ä¸æŸäº›å…¶ä»–ç‰©è´¨ç»“åˆä½¿ç”¨æ—¶ï¼Œå¯èƒ½ä¼šçªç„¶å˜å¾—å±é™©ç”šè‡³å±åŠç”Ÿå‘½ã€‚ä»¥ä¸‹åˆ—è¡¨æä¾›äº†ä¸€äº›å·²çŸ¥çš„å±é™©è”ç”¨ï¼ˆå°½ç®¡ä¸ä¿è¯åŒ…æ‹¬æ‰€æœ‰è”ç”¨ï¼‰ã€‚*

*åŠ¡å¿…è¿›è¡Œç‹¬ç«‹ç ”ç©¶ï¼ˆä¾‹å¦‚ [Google](https://www.google.com)ã€[DuckDuckGo](https://www.duckduckgo.com)ã€[PubMed](https://pubmed.ncbi.nlm.nih.gov/)ï¼‰ä»¥ç¡®ä¿ä¸¤ç§æˆ–å¤šç§ç‰©è´¨çš„ç»„åˆå¯ä»¥å®‰å…¨é£Ÿç”¨ã€‚éƒ¨åˆ†åˆ—å‡ºçš„è”ç”¨å·²ä» [TripSit](https://combo.tripsit.me) å¼•ç”¨ã€‚*

*   **[æ°§åŒ–äºšæ°®](./æ°§åŒ–äºšæ°®.md)** - ä¸¤ç§ç‰©è´¨éƒ½ä¼šå¢å¼ºå¦ä¸€ç§ç‰©è´¨å¼•èµ·çš„å…±æµå¤±è°ƒå’Œé•‡é™ä½œç”¨ï¼Œé«˜å‰‚é‡ä¸‹å¯èƒ½å¯¼è‡´æ„å¤–çš„æ„è¯†ä¸§å¤±ã€‚åœ¨æ— æ„è¯†çŠ¶æ€ä¸‹ï¼Œå¦‚æœä¸ç½®äº[æ¢å¤ä½“ä½](../æ–‡æ¡£/æ¢å¤ä½“ä½.md)ï¼Œå‘•åç‰©å¸å…¥æ˜¯ä¸€ç§é£é™©ã€‚è®°å¿†æ–­ç‰‡å¾ˆå¯èƒ½å‘ç”Ÿã€‚
*   **[è‹¯ä¸™èƒºç±»ç‰©è´¨](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‹¯ä¸™èƒºç±»ç‰©è´¨.md)** - å…´å¥‹å‰‚ä¼šå¢åŠ å‘¼å¸é¢‘ç‡ï¼Œå…è®¸æ‘„å…¥æ›´é«˜å‰‚é‡çš„é•‡é™å‰‚ã€‚å¦‚æœå…´å¥‹å‰‚å…ˆå¤±æ•ˆï¼ŒGHB å¯èƒ½ä¼šå‹å€’ä½¿ç”¨è€…å¹¶å¯¼è‡´å‘¼å¸åœæ­¢ã€‚
*   **[MDMA](./MDMA.md)** - å¤§é‡çš„ GHB/GBL å¯èƒ½ä¼šåœ¨è¯æ•ˆæ¶ˆé€€æœŸå‹å€’ MDMA çš„æ•ˆæœã€‚
*   **[å¯å¡å› ](./å¯å¡å› .md)** - å…´å¥‹å‰‚ä¼šå¢åŠ å‘¼å¸é¢‘ç‡ï¼Œå…è®¸æ‘„å…¥æ›´é«˜å‰‚é‡çš„é•‡é™å‰‚ã€‚å¦‚æœå…´å¥‹å‰‚å…ˆå¤±æ•ˆï¼ŒGHB å¯èƒ½ä¼šå‹å€’ä½¿ç”¨è€…å¹¶å¯¼è‡´å‘¼å¸åœæ­¢ã€‚åŒæ ·ï¼ŒGHB ä¹Ÿå¯èƒ½å¤±æ•ˆï¼Œç•™ä¸‹å±é™©æµ“åº¦çš„å¯å¡å› ã€‚
*   **[æ°¯èƒºé…®](./æ°¯èƒºé…®.md)** - ä¸¤ç§ç‰©è´¨éƒ½ä¼šå¼•èµ·å…±æµå¤±è°ƒï¼Œå¹¶å¸¦æ¥å‘•åå’Œæ„è¯†ä¸§å¤±çš„é£é™©ã€‚å¦‚æœä½¿ç”¨è€…åœ¨å—å½±å“æ—¶å¤±å»çŸ¥è§‰ï¼Œå¦‚æœä¸ç½®äº[æ¢å¤ä½“ä½](../æ–‡æ¡£/æ¢å¤ä½“ä½.md)ï¼Œåˆ™å­˜åœ¨ä¸¥é‡çš„å‘•åç‰©å¸å…¥é£é™©ã€‚
*   **MXE** - ä¸¤ç§ç‰©è´¨éƒ½ä¼šå¼•èµ·å…±æµå¤±è°ƒï¼Œå¹¶å¸¦æ¥å‘•åå’Œæ„è¯†ä¸§å¤±çš„é£é™©ã€‚å¦‚æœæ‚£è€…åœ¨å—å½±å“æ—¶å¤±å»çŸ¥è§‰ï¼Œå¦‚æœä¸ç½®äº[æ¢å¤ä½“ä½](../æ–‡æ¡£/æ¢å¤ä½“ä½.md)ï¼Œåˆ™å­˜åœ¨ä¸¥é‡çš„å‘•åç‰©å¸å…¥é£é™©ã€‚
*   **[å³ç¾æ²™èŠ¬](./å³ç¾æ²™èŠ¬.md)** - ä¸¤ç§ç‰©è´¨éƒ½ä¼šå¼•èµ·å…±æµå¤±è°ƒï¼Œå¹¶å¸¦æ¥å‘•åå’Œæ„è¯†ä¸§å¤±çš„é£é™©ã€‚å¦‚æœæ‚£è€…åœ¨å—å½±å“æ—¶å¤±å»çŸ¥è§‰ï¼Œå¦‚æœä¸ç½®äº[æ¢å¤ä½“ä½](../æ–‡æ¡£/æ¢å¤ä½“ä½.md)ï¼Œåˆ™å­˜åœ¨ä¸¥é‡çš„å‘•åç‰©å¸å…¥é£é™©ã€‚è¿™ç§ç»„åˆå¾ˆéš¾é¢„æµ‹ã€‚
*   **[PCP](./PCP.md)** - å…³äºè¿™ç§ç»„åˆçš„ç»†èŠ‚å°šä¸æ¸…æ¥šï¼Œä½† PCP é€šå¸¸ä»¥ä¸å¯é¢„æµ‹çš„æ–¹å¼ç›¸äº’ä½œç”¨ã€‚
*   **[é…’ç²¾](./é…’ç²¾.md)** - å³ä½¿åœ¨æä½å‰‚é‡ä¸‹ï¼Œè¿™ç§ç»„åˆä¹Ÿä¼šè¿…é€Ÿå¯¼è‡´è®°å¿†ä¸§å¤±ã€ä¸¥é‡çš„å…±æµå¤±è°ƒå’Œæ„è¯†ä¸§å¤±ã€‚åœ¨æ— æ„è¯†çŠ¶æ€ä¸‹ï¼Œå‘•åç‰©å¸å…¥çš„é£é™©å¾ˆé«˜ã€‚
*   **[é˜¿ç‰‡ç±»è¯ç‰©](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/é˜¿ç‰‡ç±»è¯ç‰©.md)** - è¿™ä¸¤ç§ç‰©è´¨å¼ºçƒˆä¸”ä¸å¯é¢„æµ‹åœ°ç›¸äº’å¢å¼ºï¼Œéå¸¸è¿…é€Ÿåœ°å¯¼è‡´æ„è¯†ä¸§å¤±ã€‚åœ¨æ— æ„è¯†çŠ¶æ€ä¸‹ï¼Œå¦‚æœä¸ç½®äº[æ¢å¤ä½“ä½](../æ–‡æ¡£/æ¢å¤ä½“ä½.md)ï¼Œå‘•åç‰©å¸å…¥æ˜¯ä¸€ç§é£é™©ã€‚
*   **Tramadol** - è¿™ç§ç»„åˆçš„é•‡é™ä½œç”¨å¯èƒ½å¯¼è‡´å±é™©çš„å‘¼å¸æŠ‘åˆ¶ã€‚
*   **[è‹¯äºŒæ°®å“ç±»ç‰©è´¨](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‹¯äºŒæ°®å“ç±»ç‰©è´¨.md)** - è¿™ä¸¤ç§ç‰©è´¨å¼ºçƒˆä¸”ä¸å¯é¢„æµ‹åœ°ç›¸äº’å¢å¼ºï¼Œéå¸¸è¿…é€Ÿåœ°å¯¼è‡´æ„è¯†ä¸§å¤±ã€‚åœ¨æ— æ„è¯†çŠ¶æ€ä¸‹ï¼Œå¦‚æœä¸ç½®äº[æ¢å¤ä½“ä½](../æ–‡æ¡£/æ¢å¤ä½“ä½.md)ï¼Œå‘•åç‰©å¸å…¥æ˜¯ä¸€ç§é£é™©ã€‚

## æ³•å¾‹åœ°ä½ <span id="Legal_status"></span>

2001 å¹´ï¼ŒGHB è¢«ç½®äºå›½é™…ç®¡åˆ¶ä¹‹ä¸‹ï¼Œåˆ—å…¥ 1971 å¹´è”åˆå›½ç²¾ç¥è¯ç‰©å…¬çº¦é™„è¡¨ IVã€‚[\[37\]](#cite_note-37)

*   **å¥¥åœ°åˆ©ï¼š** æ ¹æ® SMGï¼ˆå¥¥åœ°åˆ©éº»é†‰å“æ³•ï¼‰ï¼Œæ‹¥æœ‰ã€ç”Ÿäº§å’Œé”€å”® GHB æ˜¯éæ³•çš„ã€‚\[*æ¥æºè¯·æ±‚*\]
*   **æ¾³å¤§åˆ©äºšï¼š** GHBã€[1,4-B](../æ–‡æ¡£/è¯ç‰©å‰è¯.md) å’Œ [GBL](./GBL.md) å‡ä¸º B ç±»éæ³•è¯ç‰©ï¼Œä»¥åŠä»»ä½•å¯èƒ½çš„é…¯ã€é†šå’Œé†›ã€‚\[*æ¥æºè¯·æ±‚*\]
*   **æ™ºåˆ©ï¼š** GHB æ ¹æ®â€œLey de substancias psicotropicas y estupefacientesâ€ï¼ˆç²¾ç¥è¯ç‰©å’Œéº»é†‰å“æ³•ï¼‰è¢«åˆ—ä¸ºå—æ§è¯ç‰©ã€‚\[*æ¥æºè¯·æ±‚*\]
*   **åŠ æ‹¿å¤§ï¼š** GHB å—ã€Šå—æ§è¯ç‰©å’Œç‰©è´¨æ³•ã€‹é™„è¡¨ I ç®¡åˆ¶ã€‚é™¤éè¢«æˆæƒç”¨äºåŒ»ç–—ã€ç§‘å­¦æˆ–å·¥ä¸šç›®çš„ï¼Œå¦åˆ™é”€å”®ã€æ‹¥æœ‰å’Œç”Ÿäº§ GHB ç­‰æ´»åŠ¨å‡å±éæ³•ã€‚[\[38\]](#cite_note-38)
*   **å¾·å›½ï¼š** GHB æ˜¯ BtMG é™„è¡¨ III ä¸‹çš„å—æ§ç‰©è´¨ã€‚åªèƒ½é€šè¿‡éº»é†‰å“å¤„æ–¹å¼€å…·ã€‚æ³¨å°„åˆ¶å‰‚æœ‰ä¸€ä¸ªä¾‹å¤–ï¼Œæ¯å•ä½å«æœ‰é«˜è¾¾ 20% æˆ– 2g GHB çš„åˆ¶å‰‚è¢«è§†ä¸ºå¸¸è§„è¯ç‰©ã€‚[\[39\]](#cite_note-39)
*   **æ„å¤§åˆ©ï¼š** GHB æ˜¯â€œTesto unico sulla droga (D.P.R. 309/90)â€çš„é™„è¡¨ IV è¯ç‰©ï¼ˆTabella 4ï¼‰ã€‚å½“ç”¨äºåŒ»ç–—ç”¨é€”æ—¶ï¼Œå®ƒå±äºè¯å“ B éƒ¨åˆ†ï¼ˆTabella medicinali sezione Bï¼‰ã€‚[\[40\]](#cite_note-40)[\[41\]](#cite_note-41)
*   **é¦™æ¸¯ï¼š** GHB å—é¦™æ¸¯ç¬¬ 134 ç« å±é™©è¯ç‰©æ¡ä¾‹é™„è¡¨ 1 ç®¡åˆ¶ã€‚\[*æ¥æºè¯·æ±‚*\]
*   **æ–°è¥¿å…°ï¼š** GHBã€1,4-B å’Œ GBL å‡ä¸º B ç±»éæ³•è¯ç‰©ï¼Œä»¥åŠä»»ä½•å¯èƒ½çš„é…¯ã€é†šå’Œé†›ã€‚\[*æ¥æºè¯·æ±‚*\]
*   **æŒªå¨ï¼š** GHB è¢«è§†ä¸ºéº»é†‰å“ï¼Œä»…èƒ½é€šè¿‡å¤„æ–¹ä»¥å•†å“å Xyrem è·å¾—ã€‚\[*æ¥æºè¯·æ±‚*\]
*   **ç½—é©¬å°¼äºš**ï¼šGHB è¢«è§†ä¸ºé™„è¡¨ I éæ³•è¯ç‰©ã€‚[\[42\]](#cite_note-42)
*   **ç‘å£«ï¼š** GHB æ˜¯ Verzeichnis A ä¸‹ç‰¹åˆ«æŒ‡æ˜çš„å—æ§ç‰©è´¨ã€‚å…è®¸åŒ»ç–—ä½¿ç”¨ã€‚[\[43\]](#cite_note-43)
*   **è‹±å›½ï¼š** GHB äº 2003 å¹´ 6 æœˆè¢«åˆ—ä¸º C ç±»è¯ç‰©ã€‚\[*æ¥æºè¯·æ±‚*\]
*   **ç¾å›½ï¼š** GHB äº 2000 å¹´ 3 æœˆè¢«åˆ—å…¥ã€Šå—æ§ç‰©è´¨æ³•ã€‹é™„è¡¨ Iã€‚ç„¶è€Œï¼Œå½“ä½œä¸ºç¾Ÿä¸é…¸é’ é”€å”®æ—¶ï¼Œå®ƒè¢«è§†ä¸ºé™„è¡¨ III ç‰©è´¨ï¼Œä½†å…·æœ‰é™„è¡¨ I çš„è´©è¿å¤„ç½šã€‚[\[44\]](#cite_note-44) å®ƒæ˜¯åˆ—å…¥å¤šä¸ªé™„è¡¨çš„å‡ ç§è¯ç‰©ä¹‹ä¸€ã€‚

## å¦è§ <span id="See_also"></span>

*   [è´Ÿè´£ä»»çš„ç”¨è¯](../æ–‡æ¡£/è´Ÿè´£ä»»çš„ç”¨è¯ç´¢å¼•é¡µ.md)
*   [1,4-ä¸äºŒé†‡](../æ–‡æ¡£/è¯ç‰©å‰è¯.md)
*   [æŠ‘åˆ¶å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md)
*   [é…’ç²¾](./é…’ç²¾.md)
*   [GBL](./GBL.md)

## å¤–éƒ¨é“¾æ¥ <span id="External_links"></span>

*   [GHB (Wikipedia)](http://en.wikipedia.org/wiki/Gamma-Hydroxybutyric_acid)
*   [GHB (Erowid Vault)](https://www.erowid.org/chemicals/ghb/ghb.shtml)
*   [GHB (Isomer Design)](https://isomerdesign.com/PiHKAL/explore.php?id=12265)
*   [GHB (Drugs-Forum)](https://drugs-forum.com/wiki/GHB)

## å‚è€ƒæ–‡çŒ® <span id="References"></span>

1.  [â†‘](#cite_ref-tripsit_1-0) [*Risks of Combining Depressants - TripSit*](https://tripsit.me/combining-depressants/)
2.  â†‘ [2.0](#cite_ref-ErowidGHBVault_2-0) [2.1](#cite_ref-ErowidGHBVault_2-1) [2.2](#cite_ref-ErowidGHBVault_2-2) [*Erowid GHB Vault : Dosage*](https://www.erowid.org/chemicals/ghb/ghb_dose.shtml)
3.  [â†‘](#cite_ref-3) <http://www.reuters.com/finance/stocks/companyProfile?rpc=66&symbol=JAZZ.O>
4.  [â†‘](#cite_ref-4) [*Sodium Oxybate: MedlinePlus Drug Information*](https://medlineplus.gov/druginfo/meds/a605032.html)
5.  [â†‘](#cite_ref-5) Kluger, R., Mamelak, M., [*Pharmaceutical composition and treatment of narcolepsy*](https://patents.google.com/patent/US4738985A/en)
6.  [â†‘](#cite_ref-6) Gessa, G. L., Fadda, F., Campochiaro, C. M. di, [*Use of gamma-hydroxybutyric acid salts for preparing pharmaceutical compositions for use in the treatment of alcoholism, and the compositions obtained*](https://patents.google.com/patent/US4983632A/en)
7.  [â†‘](#cite_ref-7) <https://www.chemspider.com/Chemical-Structure.9984.html>
8.  [â†‘](#cite_ref-8) Weil, A., Rosen, W., Weil, A. (1993). *From chocolate to morphine: everything you need to know about mind-altering drugs* (Rev. and updated ed.). Houghton Mifflin. [ISBN](http://en.wikipedia.org/wiki/International_Standard_Book_Number "wikipedia:International Standard Book Number") [9780395660799](http://en.wikipedia.org/wiki/Special:BookSources/9780395660799 "wikipedia:Special:BookSources/9780395660799").
9.  [â†‘](#cite_ref-9) Mamelak, M. (1 December 1989). ["Gammahydroxybutyrate: An endogenous regulator of energy metabolism"](https://www.sciencedirect.com/science/article/pii/S0149763489800533). *Neuroscience & Biobehavioral Reviews*. **13** (4): 187â€“198. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1016/S0149-7634(89)80053-3](//doi.org/10.1016%2FS0149-7634%2889%2980053-3). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0149-7634](//www.worldcat.org/issn/0149-7634).
10. [â†‘](#cite_ref-10) Wu, Y., Ali, S., Ahmadian, G., Liu, C. C., Wang, Y. T., Gibson, K. M., Calver, A. R., Francis, J., Pangalos, M. N., Carter Snead, O. (1 December 2004). ["Î³-Hydroxybutyric acid (GHB) and Î³-aminobutyric acidB receptor (GABABR) binding sites are distinctive from one another: molecular evidence"](https://www.sciencedirect.com/science/article/pii/S0028390804002527). *Neuropharmacology*. **47** (8): 1146â€“1156. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1016/j.neuropharm.2004.08.019](//doi.org/10.1016%2Fj.neuropharm.2004.08.019). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0028-3908](//www.worldcat.org/issn/0028-3908).
11. â†‘ [11.0](#cite_ref-Maitre2005_11-0) [11.1](#cite_ref-Maitre2005_11-1) Maitre, M., Humbert, J.-P., Kemmel, V., Aunis, D., Andriamampandry, C. (1 March 2005). ["MÃ©canismes d'action d'un mÃ©dicament dÃ©tournÃ© : le Î³-hydroxybutyrate"](https://www.medecinesciences.org/articles/medsci/abs/2005/03/medsci2005213p284/medsci2005213p284.html). *mÃ©decine/sciences*. **21** (3): 284â€“289. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1051/medsci/2005213284](//doi.org/10.1051%2Fmedsci%2F2005213284). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0767-0974](//www.worldcat.org/issn/0767-0974).
12. â†‘ [12.0](#cite_ref-Dimitrijevic2005_12-0) [12.1](#cite_ref-Dimitrijevic2005_12-1) Dimitrijevic, N., Dzitoyeva, S., Satta, R., Imbesi, M., Yildiz, S., Manev, H. (20 September 2005). ["Drosophila GABAB receptors are involved in behavioral effects of Î³-hydroxybutyric acid (GHB)"](https://www.sciencedirect.com/science/article/pii/S0014299905007442). *European Journal of Pharmacology*. **519** (3): 246â€“252. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1016/j.ejphar.2005.07.016](//doi.org/10.1016%2Fj.ejphar.2005.07.016). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0014-2999](//www.worldcat.org/issn/0014-2999).
13. â†‘ [13.0](#cite_ref-Castelli2003_13-0) [13.1](#cite_ref-Castelli2003_13-1) Castelli, M. P., Ferraro, L., Mocci, I., Carta, F., Carai, M. A. M., Antonelli, T., Tanganelli, S., Cignarella, G., Gessa, G. L. (19 September 2003). ["Selective Î³-hydroxybutyric acid receptor ligands increase extracellular glutamate in the hippocampus, but fail to activate G protein and to produce the sedative/hypnotic effect of Î³-hydroxybutyric acid: Î³-Hydroxybutyric analogues on glutamate levels"](http://doi.wiley.com/10.1046/j.1471-4159.2003.02037.x). *Journal of Neurochemistry*. **87** (3): 722â€“732. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1046/j.1471-4159.2003.02037.x](//doi.org/10.1046%2Fj.1471-4159.2003.02037.x). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0022-3042](//www.worldcat.org/issn/0022-3042).
14. [â†‘](#cite_ref-14) Maitre, M., Hechler, V., Vayer, P., Gobaille, S., Cash, C. D., Schmitt, M., Bourguignon, J. J. (November 1990). "A specific gamma-hydroxybutyrate receptor ligand possesses both antagonistic and anticonvulsant properties". *The Journal of Pharmacology and Experimental Therapeutics*. **255** (2): 657â€“663. [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0022-3565](//www.worldcat.org/issn/0022-3565).
15. [â†‘](#cite_ref-15) Smolders, I., De Klippel, N., Sarre, S., Ebinger, G., Michotte, Y. (15 September 1995). ["Tonic GABA-ergic modulation of striatal dopamine release studied by in vivo microdialysis in the freely moving rat"](https://www.sciencedirect.com/science/article/pii/001429999500369V). *European Journal of Pharmacology*. **284** (1): 83â€“91. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1016/0014-2999(95)00369-V](//doi.org/10.1016%2F0014-2999%2895%2900369-V). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0014-2999](//www.worldcat.org/issn/0014-2999).
16. [â†‘](#cite_ref-Nutt_2010_16-0) Nutt DJ, King LA, Phillips LD (November 2010). "Drug harms in the UK: a multicriteria decision analysis". *Lancet*. **376** (9752): 1558â€“1565. [CiteSeerX](http://en.wikipedia.org/wiki/CiteSeerX "wikipedia:CiteSeerX") [10.1.1.690.1283](//citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.690.1283)â€¯![Freely accessible](https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/langen-gb-20px-Lock-green.svg.png "Freely accessible"). [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1016/S0140-6736(10)61462-6](//doi.org/10.1016%2FS0140-6736%2810%2961462-6). [PMID](http://en.wikipedia.org/wiki/PubMed_Identifier "wikipedia:PubMed Identifier") [21036393](//www.ncbi.nlm.nih.gov/pubmed/21036393).  Unknown parameter `|s2cid=` ignored ([help](/w/index.php?title=Help:CS1_errors&action=edit&redlink=1 "Help:CS1 errors (page does not exist)"))
17. [â†‘](#cite_ref-17) Nutt, D., King, L. A., Saulsbury, W., Blakemore, C. (24 March 2007). ["Development of a rational scale to assess the harm of drugs of potential misuse"](https://www.sciencedirect.com/science/article/pii/S0140673607604644). *The Lancet*. **369** (9566): 1047â€“1053. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1016/S0140-6736(07)60464-4](//doi.org/10.1016%2FS0140-6736%2807%2960464-4). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0140-6736](//www.worldcat.org/issn/0140-6736).
18. [â†‘](#cite_ref-18) [*GHB - Erowid Exp - â€œGHB Overdoses & Poisoningsâ€*](https://www.erowid.org/experiences/exp.php?ID=1926)
19. [â†‘](#cite_ref-19) Zvosec, D. L., Smith, S. W., Porrata, T., Strobl, A. Q., Dyer, J. E. (March 2011). "Case series of 226 Î³-hydroxybutyrate-associated deaths: lethal toxicity and trauma". *The American Journal of Emergency Medicine*. **29** (3): 319â€“332. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1016/j.ajem.2009.11.008](//doi.org/10.1016%2Fj.ajem.2009.11.008). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1532-8171](//www.worldcat.org/issn/1532-8171).
20. [â†‘](#cite_ref-20) Ferrara, S., Zotti, S., Tedeschi, L., Frison, G., Castagna, F., Gallimberti, L., Gessa, G., Palatini, P. (September 1992). ["Pharmacokinetics of gamma-hydroxybutyric acid in alcohol dependent patients after single and repeated oral doses"](https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2125.1992.tb04129.x). *British Journal of Clinical Pharmacology*. **34** (3): 231â€“235. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1111/j.1365-2125.1992.tb04129.x](//doi.org/10.1111%2Fj.1365-2125.1992.tb04129.x). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0306-5251](//www.worldcat.org/issn/0306-5251).
21. [â†‘](#cite_ref-21) Laborit, H. (January 1972). "Correlations between protein and serotonin synthesis during various activities of the central nervous system (slow and desynchronized sleep, learning and memory, sexual activity, morphine tolerance, aggressiveness, and pharmacological action of sodium gamma-hydroxybutyrate)". *Research Communications in Chemical Pathology and Pharmacology*. **3** (1): 51â€“81. [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0034-5164](//www.worldcat.org/issn/0034-5164).
22. [â†‘](#cite_ref-22) Amsterdam JV, Brunt TM, Pereira FR, Crunelle CL, Brink WVD. [Cognitive Impairment Following Clinical or Recreational Use of Gammahydroxybutyric Acid (GHB): A Systematic Review.](https://web.archive.org/web/20230313103920/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9878963/) Curr Neuropharmacol. 2022;20(4):809-819.
23. [â†‘](#cite_ref-23) Sircar, R., Basak, A. (1 December 2004). ["Adolescent Î³-hydroxybutyric acid exposure decreases cortical N-methyl-d-aspartate receptor and impairs spatial learning"](https://www.sciencedirect.com/science/article/pii/S009130570400320X). *Pharmacology Biochemistry and Behavior*. **79** (4): 701â€“708. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1016/j.pbb.2004.09.022](//doi.org/10.1016%2Fj.pbb.2004.09.022). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0091-3057](//www.worldcat.org/issn/0091-3057).
24. [â†‘](#cite_ref-24) GarcÃ­a, F. B., Pedraza, C., Arias, J. L., Navarro, J. F. (August 2006). "[Effects of subchronic administration of gammahydroxybutyrate (GHB) on spatial working memory in rats]". *Psicothema*. **18** (3): 519â€“524. [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0214-9915](//www.worldcat.org/issn/0214-9915).
25. [â†‘](#cite_ref-25) Sircar, R., Basak, A., Sircar, D. (October 2008). ["Î³-Hydroxybutyric Acid-Induced Cognitive Deficits in the Female Adolescent Rat"](http://doi.wiley.com/10.1196/annals.1432.044). *Annals of the New York Academy of Sciences*. **1139** (1): 386â€“389. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1196/annals.1432.044](//doi.org/10.1196%2Fannals.1432.044). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0077-8923](//www.worldcat.org/issn/0077-8923).
26. [â†‘](#cite_ref-26) Pedraza, C., GarcÃ­a, F. B., Navarro, J. F. (October 2009). ["Neurotoxic effects induced by gammahydroxybutyric acid (GHB) in male rats"](https://academic.oup.com/ijnp/article-lookup/doi/10.1017/S1461145709000157). *The International Journal of Neuropsychopharmacology*. **12** (09): 1165. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1017/S1461145709000157](//doi.org/10.1017%2FS1461145709000157). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1461-1457](//www.worldcat.org/issn/1461-1457).
27. [â†‘](#cite_ref-27) Sircar, R., Basak, A. (December 2004). "Adolescent gamma-hydroxybutyric acid exposure decreases cortical N-methyl-D-aspartate receptor and impairs spatial learning". *Pharmacology, Biochemistry, and Behavior*. **79** (4): 701â€“708. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1016/j.pbb.2004.09.022](//doi.org/10.1016%2Fj.pbb.2004.09.022). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0091-3057](//www.worldcat.org/issn/0091-3057).
28. [â†‘](#cite_ref-28) <https://www.erowid.org/chemicals/ghb/ghb_health.shtml>
29. â†‘ [29.0](#cite_ref-GHB_29-0) [29.1](#cite_ref-GHB_29-1) GHB Withdrawal Syndrome | Texas Commission on Alcohol and Drug Abuse | <https://www.erowid.org/chemicals/ghb/ghb_addiction2.pdf>
30. [â†‘](#cite_ref-30) Kim, S. Y., Barker, J. C., Anderson, I. B., Dyer, J. E., Earnest, G., Blanc, P. D. (2008). ["Systematic Assessment of Gamma Hydroxybutyrate (GHB) Effects During and After Acute Intoxication"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2759403/). *The American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions*. **17** (4): 312â€“318. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1080/10550490802138988](//doi.org/10.1080%2F10550490802138988). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1055-0496](//www.worldcat.org/issn/1055-0496).
31. [â†‘](#cite_ref-31) Carter, L. P., Pardi, D., Gorsline, J., Griffiths, R. R. (1 September 2009). ["Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (XyremÂ®): differences in characteristics and misuse"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2713368/). *Drug and alcohol dependence*. **104** (1â€“2): 1â€“10. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1016/j.drugalcdep.2009.04.012](//doi.org/10.1016%2Fj.drugalcdep.2009.04.012). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0376-8716](//www.worldcat.org/issn/0376-8716).
32. [â†‘](#cite_ref-32) Dyer, J. E., Roth, B., Hyma, B. A. (February 2001). "Gamma-hydroxybutyrate withdrawal syndrome". *Annals of Emergency Medicine*. **37** (2): 147â€“153. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1067/mem.2001.112985](//doi.org/10.1067%2Fmem.2001.112985). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0196-0644](//www.worldcat.org/issn/0196-0644).
33. [â†‘](#cite_ref-33) <https://drugs-forum.com/threads/important-ghb-gbl-addiction-withdrawal.43390/page-4>
34. [â†‘](#cite_ref-34) Galloway, G. P., Frederick, S. L., Staggers, F. E., Gonzales, M., Stalcup, S. A., Smith, D. E. (January 1997). ["Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence"](https://onlinelibrary.wiley.com/doi/10.1111/j.1360-0443.1997.tb03640.x). *Addiction*. **92** (1): 89â€“96. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1111/j.1360-0443.1997.tb03640.x](//doi.org/10.1111%2Fj.1360-0443.1997.tb03640.x). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0965-2140](//www.worldcat.org/issn/0965-2140).
35. [â†‘](#cite_ref-35) Colombo, G., Agabio, R., Lobina, C., Reali, R., Fadda, F., Gessa, G. L. (6 February 1995). ["Cross-tolerance to ethanol and Î³-hydroxybutyric acid"](https://www.sciencedirect.com/science/article/pii/0014299994006873). *European Journal of Pharmacology*. **273** (3): 235â€“238. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1016/0014-2999(94)00687-3](//doi.org/10.1016%2F0014-2999%2894%2900687-3). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0014-2999](//www.worldcat.org/issn/0014-2999).
36. [â†‘](#cite_ref-36) Smith, M. A., Gergans, S. R., Lyle, M. A. (15 December 2006). ["The motor-impairing effects of GABAA and GABAB agonists in Î³-hydroxybutyrate (GHB)-treated rats: Cross-tolerance to baclofen but not flunitrazepam"](https://www.sciencedirect.com/science/article/pii/S0014299906009964). *European Journal of Pharmacology*. **552** (1): 83â€“89. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1016/j.ejphar.2006.08.080](//doi.org/10.1016%2Fj.ejphar.2006.08.080). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0014-2999](//www.worldcat.org/issn/0014-2999).
37. [â†‘](#cite_ref-37) ["Control measures"](https://www.emcdda.europa.eu/html.cfm/index16783EN.html). European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Retrieved October 20, 2020.
38. [â†‘](#cite_ref-38) Canada, H. (2012), [*GHB*](https://www.canada.ca/en/health-canada/services/substance-use/controlled-illegal-drugs/ghb.html)
39. [â†‘](#cite_ref-39) [*Anlage III BtMG - Einzelnorm*](http://www.gesetze-im-internet.de/btmg_1981/anlage_iii.html)
40. [â†‘](#cite_ref-40) Tabella IV Sostanze stupefacenti <http://www.salute.gov.it/imgs/C_17_pagineAree_3729_listaFile_itemName_3_file.pdf>
41. [â†‘](#cite_ref-41) Tabella Medicinali D.P.R. 309/90 <http://www.salute.gov.it/imgs/C_17_pagineAree_3729_listaFile_itemName_4_file.xls>
42. [â†‘](#cite_ref-42) <https://legislatie.just.ro/Public/DetaliiDocument/23629>
43. [â†‘](#cite_ref-43) ["Verordnung des EDI Ã¼ber die Verzeichnisse der BetÃ¤ubungsmittel, psychotropen Stoffe, VorlÃ¤uferstoffe und Hilfschemikalien"](https://www.admin.ch/opc/de/classified-compilation/20101220/index.html) (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020.
44. [â†‘](#cite_ref-44) [*Laws*](http://web.archive.org/web/20100116121252/http://www.projectghb.org/laws.htm), 2010